Everolimus
CAS: 159351-69-6
Name:
Everolimus
Other names:
Afinitor; Certican; Zortress; SDZ-RAD, RAD001; Everolimus [USAN]; 42-O-(2-Hydroxyethyl)rapamycin; RAD 001
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus’ effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Interactions
Description
UniProt ID
Protein: Peptidyl-prolyl cis-trans isomerase FKBP1A, Gene: FKBP1A
Protein: Serine/threonine-protein kinase mTOR, Gene: MTOR
Protein: Solute carrier organic anion transporter family member 1A2, Gene: SLCO1A2
Gene: SLCO1B1
Protein: Solute carrier organic anion transporter family member 1B3, Gene: SLCO1B3
Toxicity
- oral LD50 [mouse] mg/kg
- Unavailable
- oral LD50 [rat] mg/kg
- > 0.0
- oral LD50 [rabbit] mg/kg
- Unavailable
Antibacterial
No
Antifungal
No
Antiviral
No
Longevity mechanisms activation
No dataSuppression of aging mechanisms
No dataRelation to biomarkers of Aging
Stimulation of autophagy; Improves immune function in the elderly
Relation to aging associated genes
No data available
Model organism
ModelDrosophila melanogaster
SrainOregon-R-C
Sex—
Age of treatment—
Experimental conditions
Not availableLife Extension
- Mean LS (%)
- 16.6
- Median LS (%)
- —
- Mortality rate derease (%)
- —
- Max LS (%)
- —
- Cell CLS
- —
- Cell RLS
- —
Concentration wth maximum effect
3 mM
More info about experiment
Opposite effectNo